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Summary Objective: To investigate the relationship between quantitative EEG (QEEG)
scores and ‘‘complicating factors’’ (psychopathology, true pharmacoresistance, neu-
rological symptoms) in idiopathic generalised epilepsy (IGE). Methods: 35 newly re-
ferred, newly diagnosed, unmedicated IGE patients were collected in a prospective
and random manner. Standard neuro-psychiatric and EEG examination was done. The
patients were treated and controlled at regular visits. After 2 years of follow-up, clin-
ical data were summarised and were compared to QEEG results. Clinical target items
were neurologic and psychiatric abnormalities, proven pharmacoresistance. Patients
with at least one of these items were labelled ‘‘complicated’’, whereas patients
without these additional handicap were labelled as ‘‘uncomplicated’’. The 12 QEEG
target variables were: Z-transformed absolute power values for three (anterior, cen-
tral, posterior) brain regions and four frequency bands (1.5—3.5; 3.5—7.5; 7.5—12.5;
12.5—25.0Hz). QEEG scores outside the±2.5 Z range were accepted as abnormal. The
overall QEEG result was classiﬁed as normal (0—2 abnormal scores), or pathological (3
or more abnormal scores). Clinical and QEEG results were correlated. Results: All pa-
tients with psychopathology showed 4—8 positive pathological scores (power excess
not conﬁned to a single cortical region or frequency band). The two patients with
pure pharmacoresistance showed pathological negative values (delta power deﬁcit)
all over the scalp. Statistically signiﬁcant (P < 0.001) association was found between
patients with uncomplicated IGE and normal QEEG, and between complicated IGE and
pathological QEEG. Patients with neurological items had normal QEEG. Conclusion:
Higher degree of cortical dysfunction (as assessed in the clinical setting) is reﬂected
by higher degree of QEEG abnormalities. QEEG analysis can differentiate between IGE
patients with or without psychopathology. Forecasting psychopathology may be the
practical application of the ﬁndings.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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Introduction
Idiopathic generalised epilepsy (IGE) syndromes
are overlapping electro-clinical entities. According
to the deﬁnition elaborated by an ILAE Committee,
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‘‘the patient usually has a normal interictal state,
without neurologic and neuroradiologic signs’’.1
The majority of IGE patients can be successfully
treated with standard antiepileptic drugs.2 Diag-
nosis and treatment is not always easy, however,
15.5% of juvenile myoclonic epilepsy patients are
resistant to antiepileptic drugs despite correct
therapy and lifestyle.3About 25% of these pa-
tients has psychiatric and psychological problems
that can counteract therapeutic efforts.4,5 The
negative impact of cognitive and personality dis-
turbances on seizure control and quality of life
has been conﬁrmed repeatedly. Besides average
intelligence, these young people are inclined to
follow their momentary feelings and impulsions
which results in instable, childish behaviour some-
times reaching the degree of levity. Planning their
own future is often lacking because they are ‘‘. . .
more inclined to take things as they come than
to act in accordance with an independent line of
conduct’’ as Janz wrote.4 This sort of personality
disturbance results in neglecting and dissimulat-
ing seizures, irregular intake of medication, ig-
noring proven seizure-provoking factors like sleep
deprivation. In this way the patients are likely
to suffer of self-provoked seizures and, in turn,
self-perpetuated social maladjustment.4,6—8 Neu-
rological signs and abnormal radiological ﬁndings
(in standard CT and MRI scans) may occur but have
no impact on treatment and prognosis.3,9 Focal
features in IGE patients can hinder correct diagno-
sis, however.10 Early recognition of these difﬁcul-
ties, in particular, psychopathology, can promote
planning of effective treatment strategies.6,8 The
problem is that recognition of these complicating
factors is not always easy. Neurological signs and
mental retardation can be recognised at the ﬁrst
examination. In contrast, a peculiar personality
trait that highly counteracts effective treatment4
may be unrecognised at the ﬁrst visit. Usually,
analysis of recurrent therapeutic failures highlights
that psychopathology is the cause of pseudoresis-
tance. In cases of ‘‘pseudoresistance’’, the causes
of persistent seizures are irregular intake of the
drug and/or ignoring appropriate lifestyle by the
patients. Also true pharmacoresistance cannot be
diagnosed at the ﬁrst visit.
Advanced neuroimaging studies and neuropathol-
ogy revealed that the brain of IGE patients is
not entirely normal in terms of structure and
function.11—16 Mild cortical pathology not de-
tected by routine MRI probably contributes to
neuro-psychiatric problems.7,17 Interestingly,
the percentage of IGE patients with psychiatric
disturbances4,5 is roughly equal to the percentage
of IGE patients with signiﬁcant cortical abnormali-
ties detected by voxel-based MRI.18 Some indirect
evidence suggest that cortical pathology might
contribute to pharmacoresistance, too.3,19 In the
light of these ﬁndings, it is reasonable to suppose
that IGE patients with complicating factors have
higher degree of cortical dysfunction than IGE
patients without such additional handicaps. For
several reasons, sophisticated neuroimaging can
hardly be used as a routine screening method for
cerebral abnormalities that are associated with
psychopathology and pharmacoresistance. In con-
trast, quantitative EEG (QEEG) analysis is a proven
tool to assess the degree and pattern of cortical
dysfunction.20,21 In a prior study we found that a
group of IGE patients showed signiﬁcant diffuse
quantitative EEG alterations as compared to a
healthy control group.22 In that study we did not
address the distribution of the QEEG abnormali-
ties across the patients. Now we formulated and
tested the hypotheses that (1) IGE patients do not
have the same degree of QEEG abnormality, (2)
higher degree of cortical dysfunction (as assessed
in the clinical setting) might be reﬂected by higher
degree of QEEG abnormalities.
Methods
The design of this study was approved by the Local
Ethics Committee of the Institution. In a period
of 2.5 years, all the newly referred patients who
fulﬁlled inclusion criteria entered this investiga-
tion. Inclusion criteria were as follows: (1) newly
diagnosed IGE (juvenile absence epilepsy, juve-
nile myoclonic epilepsy, epilepsy with generalised
tonic-clonic seizures on awakening). The diagnosis
was based on concordant clinical and EEG results.1
Deﬁnition of the term ‘‘newly diagnosed’’ was a
seizure history of 1 year or less. (2) No systemic or
neuro-psychiatric illness except IGE. (3) No regular
alcohol or drug use or misuse (contraceptives were
allowed). (4) Freedom from any medications in the
5 days before EEG investigation. (5) Standard EEG
record of good quality, according to recommenda-
tions for quantitative EEG studies.23 Patients who
had got generalised tonic-clonic seizures in the 3
days before EEG, or took any medication in the
5 days before EEG investigation, were excluded.
All the patients were diagnosed, treated, and fol-
lowed at the Outpatient Service of our Institution.
History taking, routine neuro-psychiatric evalua-
tion, conventional EEG evaluation were done at
the ﬁrst visit. Indications of cranial MRI were the
presence of neurological items, and later, phar-
macoresistance. Treatment with valproate was
indicated in all the patients. No extra investigation
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was done, no treatment was postponed or tapered
off for study purposes. Patients were followed at
regular visits. In case of therapeutic failure, po-
tential causes were analysed. In difﬁcult-to-treat
cases other drugs (lamotrigine, ethosuximide) or
combinations of these drugs were administered.
In cases of personality disturbances and pseudore-
sistance, psychotherapy was indicated. Final eval-
uation of the patients was done after 2 years of
follow-up. Based on the clinical data accumulated
in this period, patients were classiﬁed as uncom-
plicated (no neurologic or mental problems inter-
ictally, responders to drugs), or complicated (any
cerebral damage in the patient’s history, neurolog-
ical symptoms, psychiatric symptoms, personality
disorder, pharmacoresistance). In this paper, the
term ‘‘personality disorder’’ refers to the peculiar
trait that is characteristic to IGE patients,4 as de-
scribed in the Introduction section of this paper.
Part of this personality disturbance is neglect-
ing and dissimulating seizures, irregular intake of
medication, ignoring proven seizure-provoking fac-
tors. As a consequence, the patients are prone to
self-perpetuated social maladjustment. This con-
dition should be recognised in the clinical setting
as soon as possible; psychological testing is not
necessary.4,6,8
All the EEG recordings were done in the forenoon
hours, in the same semi-isolated room, with the
same equipment (Brain Quick BQ240) by trained
personnel, according to recommended standards
for quantitative EEG studies.23 Silver—silver chlo-
ride electrodes were placed according to the
10—20 system, ﬁxed by appropriate adhesive and
conductive gel. Impedances did not exceed 5 k.
19-channel EEG was recorded against a linked ears
reference. In addition, two bipolar derivations
were used to identify oculographic and myogenic
artefacts. 12-bit on-line digitisation was used.
Sampling frequency was 128 s−1. Forty minutes
EEG was recorded in the resting, eyes-closed con-
dition. The patients1 level of vigilance was verbally
checked during the recording. EEG records were
stored on optical disc. Off-line frequency analy-
sis started with data ﬁle conversion to the format
of the Neurometric Analysis System (NAS, Version
23.5). Sixty 2-s epochs reﬂecting relaxed—waking
state of the subjects were selected for spec-
tral analysis. Sample selection and analysis was
done blindly, without knowing the patient’s name
and clinical data. Our standardised epoch selec-
tion protocol was used. Epoch inclusion criteria
were: (1) presence of continuous physiological
(‘‘waking’’ or ‘‘resting’’) alpha activity with alpha
voltage maximum in posterior regions; (2) absence
of artefacts, epileptiform or other nonstation-
ary elements; (3) absence of patterns indicating
drowsiness or arousal. After ﬁnal visual revision of
the edited epochs, they were submitted to Fast
Fourier Transform (FFT). Leakage was reduced
by Hanning window. Data of the 60 epochs were
averaged. Absolute band power was computed
for 19 monopolar derivations and four frequency
bands (delta: 1.5—3.5Hz, theta: 3.5—7.5Hz, alpha:
7.5—12.5Hz, beta: 12.5—25.0Hz). NAS evaluated
all neurometric parameters relative to its own nor-
mative database, using age-regression equations.
Independent of age, sex and derivation, devia-
tions of the individual values from the normative
mean were expressed in Z-score.24 In order to get
regional spectral variables, electrode-related val-
ues were compressed by averaging. Delta, theta,
alpha, beta power was computed for anterior re-
gion (ANT, composed of Fp1, Fp2, F3, F4, F7, F8,
Fz values), central region (CENT, composed of T3,
T4, C3, C4, Cz values), and posterior region (POST,
composed of P3, P4, Pz, T5, T6, O1, O2 values).
Deviation of these 12 EEG variables from the
mean (Z = 0) were evaluated in all the patients.
Deviations of (Z > ±2.5) were scored as abnormal.
The number and distribution of abnormal neuro-
metric scores were compared in the patients with
and without complicating factors.
Depending on the amount of abnormal scores,
the QEEG ﬁnding was classiﬁed as ‘‘normal QEEG’’
(less than two abnormal scores), or, ‘‘pathological
QEEG’’ (two or more abnormal scores). Binomial
distributions were analysed by means of Fisher’s
exact test (GraphPad Prism 2.0). Differences with
P ≤ 0.05 were accepted as statistically signiﬁcant.
Results
Thirty-ﬁve patients were investigated, treated and
controlled (16 males, 19 females, age limits: 12—24
years, average: 17 years). Their clinical data are
summarised in Table 1. Eleven patients were classi-
ﬁed as complicated. Neurological items were found
in three patients; their cranial MRI was within
normal limits, however. Minor psychiatric distur-
bances were diagnosed in two patients (mild men-
tal retardation and compulsive self-stimulation,
respectively) at the ﬁrst investigation. Personal-
ity disorder of the Janz type4 was found in three
patients who had juvenile myoclonic epilepsy. It
was never identiﬁed at the initial investigation,
but could be recognised at follow-up visits, within
2 years after the ﬁrst visit. One patient displayed
absence-like pseudoseizures in the course of the
illness. Treatment was effective in 32 patients. De-
spite difﬁculties due to non-compliance, also two
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Table 1 Clinical and quantitative EEG data of the patients.
Band Clinical items ANT CENT POST
Patient 1
Delta 0.31088 0.847608 0.491416
Theta 1.424824 1.65845 0.016648
Alpha 1.929123 1.47067 1.001024
Beta 1.802924 1.265155 0.904999
Patient 2
Delta Right central facial palsy −1.63885 −0.82875 −1.03608
Theta 0.377688 0.828789 0.524203
Alpha 0.763651 0.438586 0.205375
Beta 0.016373 0.089472 −0.03316
Patient 3
Delta 0.012759 0.166161 −0.1496
Theta 1.481874 1.49589 1.556829
Alpha 0.944188 0.807005 0.425343
Beta 0.822654 0.512587 0.349063
Patient 4
Delta Mild mental retardation 3.065305 2.249343 1.729534
Theta 4.286108 3.039844 2.625455
Alpha 3.228347 2.88906 1.33583
Beta 4.016199 2.51891 1.786904
Patient 5
Delta Personality disorder 1.801816 3.322929 2.595404
Theta 4.923313 4.620277 2.823014
Alpha 3.026751 2.727511 1.438308
Beta 2.238273 1.822896 1.173346
Patient 6
Delta −0.0144 0.695721 0.792229
Theta 0.910841 0.6609 0.389974
Alpha −0.44227 −0.18263 −0.18567
Beta 2.293835 1.086619 0.10202
Patient 7
Delta −0.65629 −0.39542 0.871796
Theta 0.015121 0.40871 1.008864
Alpha 1.300082 1.51135 1.028962
Beta 1.280231 1.195937 1.125488
Patient 8
Delta Personality disorder and
pharmacoresistance
2.429249 2.278049 4.02887
Theta 5.304621 4.446773 5.390082
Alpha 3.151268 2.576996 2.080613
Beta 3.512075 2.422483 2.736306
Patient 9
Delta −0.92326 −0.91705 −0.5878
Theta 0.724819 0.349741 1.124451
Alpha −0.1259 −0.34973 −0.15741
Beta −0.27367 −0.79593 −0.78858
Patient 10
Delta −0.76201 −0.79149 −1.0714
Theta −0.02919 0.105787 −0.50964
Alpha 0.844512 0.745494 0.386925
Beta 0.867955 0.332503 −0.27622
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Table 1 (Continued )
Band Clinical items ANT CENT POST
Patient 11
Delta 1.010249 0.819516 1.376778
Theta 2.611484 2.385491 1.844083
Alpha 2.161055 2.01015 1.441971
Beta 0.458882 0.389795 0.329511
Patient 12
Delta Pharmacoresistance −3.20185 −2.71718 −2.67932
Theta −1.50301 −0.90068 −1.67703
Alpha −1.23073 −1.14346 −1.19992
Beta −1.25992 −1.36071 −1.56627
Patient 13
Delta −1.03946 −0.57796 −0.64287
Theta −0.21173 −0.22574 −0.24023
Alpha 0.314134 0.354242 0.272119
Beta 0.116182 0.050746 −0.17668
Patient 14
Delta Cerebral concussion in
patient’s history
−2.5971 −1.69692 −2.05564
Theta −1.11202 −0.70517 −1.1994
Alpha 1.361125 0.192236 −0.50236
Beta 0.934795 0.778545 −0.10705
Patient 15
Delta Personality disorder 2.226824 2.412144 2.901531
Theta 4.602868 4.471317 4.344932
Alpha 2.140356 2.399588 1.517922
Beta 2.359571 1.997874 1.360339
Patient 16
Delta 0.187624 0.246773 0.78972
Theta 0.805323 0.911677 1.421761
Alpha 2.354146 1.896885 1.781106
Beta 0.791241 0.89516 1.085975
Patient 17
Delta 0.678467 1.276634 1.280058
Theta 1.885425 1.854698 1.767609
Alpha 2.039536 1.896808 1.519539
Beta 2.405804 2.136765 2.14372
Patient 18
Delta −1.52188 −0.86952 −0.93473
Theta −0.74972 −0.52789 −0.88522
Alpha 1.036004 0.847684 0.8332
Beta 0.977996 0.686631 0.548921
Patient 19
Delta 1.254199 1.429218 1.59811
Theta 4.154491 3.807553 2.410176
Alpha 2.740311 3.005122 1.925584
Beta 2.468215 2.30959 1.717678
Patient 20
Delta 0.433856 0.485773 1.189957
Theta 1.544273 1.37124 1.232523
Alpha 2.234489 1.854433 1.371282
Beta 0.672631 0.455436 0.32823
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Table 1 (Continued )
Band Clinical items ANT CENT POST
Patient 21
Delta Pharmacoresistance −3.23486 −3.05815 −2.93852
Theta −2.16056 −2.17171 −2.15926
Alpha −1.97948 −1.85067 −1.73364
Beta 0.232642 −1.09746 −1.21954
Patient 22
Delta −1.5739 −1.57027 −1.73257
Theta −0.30775 −0.43832 −0.80225
Alpha 1.582012 1.08266 0.356632
Beta 0.24162 −0.04525 −0.45494
Patient 23
Delta −0.89126 −0.05732 −0.11697
Theta 0.203397 0.532569 0.348521
Alpha 0.3083 0.385621 −0.2029
Beta 0.48674 0.506083 0.457137
Patient 24
Delta 0.55479 1.085419 0.941792
Theta 2.279121 2.393341 1.572294
Alpha 0.694275 0.736635 0.168982
Beta 1.331664 1.056981 0.519622
Patient 25
Delta 1.33401 1.598367 2.673381
Theta 2.277134 2.237014 3.041324
Alpha 1.863792 1.858197 2.192263
Beta 2.085814 2.149643 2.478859
Patient 26
Delta −2.14925 −0.67237 −0.94602
Theta −0.44257 0.312179 0.000849
Alpha 1.219333 2.272273 1.081031
Beta 0.205117 0.780274 0.741893
Patient 27
Delta Self-induction of seizures 2.376185 1.996173 2.346125
Theta 3.164408 2.33983 2.66294
Alpha 2.767684 1.7987 2.04938
Beta 3.311401 2.041146 2.795052
Patient 28
Delta Perinatal hypoxya −0.04489 0.325436 1.295653
Theta −0.27276 −0.01253 0.727034
Alpha 2.24829 1.428922 1.882709
Beta 1.189696 0.98267 1.827979
Patient 29
Delta −1.75831 −1.37801 −1.48549
Theta −0.39165 −0.79838 −1.07742
Alpha 0.036373 0.081404 −0.20156
Beta −0.8614 −0.97133 −1.35139
Patient 30
Delta 0.720329 1.607432 1.382499
Theta 2.05531 2.079673 1.776112
Alpha 2.18563 2.02664 1.539772
Beta 3.634551 2.490341 1.698804
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Table 1 (Continued )
Band Clinical items ANT CENT POST
Patient 31
Delta −0.07772 0.39282 −0.10401
Theta 1.584289 1.59508 1.298563
Alpha 0.499498 1.091664 0.356403
Beta 0.599989 0.576474 −0.08987
Patient 32
Delta −0.66 0.761651 1.680449
Theta 0.127522 0.860599 0.970948
Alpha 1.440479 1.303 1.179837
Beta 0.60853 0.891097 0.750859
Patient 33
Delta Absence-like pseudoseizures 1.236846 1.02043 1.292326
Theta 2.795835 3.350303 2.982875
Alpha 1.839878 2.235002 1.408266
Beta 3.614839 3.121821 2.404069
Patient 34
Delta 0.811427 1.142138 0.810987
Theta 2.361777 2.418365 2.104271
Alpha 2.033728 2.176713 1.464969
Beta 2.964085 2.461992 1.675566
Patient 35
Delta 0.438445 0.521919 0.679708
Theta 2.388942 1.924981 1.802096
Alpha 1.039927 0.776619 0.824221
Beta 0.484722 0.140263 −0.16644
Z-transformed absolute power data for four frequency bands and three cortical regions (ANT: anterior, CENT:
central, POST: posterior). Bold numerals indicate (Z > ±2.5) scores.
patients with personality disorder could be treated
successfully. One patient with personality disorder
and two patients without neuro-psychiatric items
showed proven pharmacoresistance to valproate,
lamotrigine, ethosuximide, and combinations.
Neurometric analysis and consecutive data com-
pression resulted in 12 neurometric scores in each
patient. The distribution of pathological scores
across patients, cortical regions, and frequency
bands is tabulated in Table 1. The results can be
summarised as follows:
1. Clusters of positive abnormal values were found
in all the patients with psychiatric items (pa-
tients no. 4, 5, 8, 15, 27, and 33). Abnormal
scores did not show speciﬁc linkage to any cor-
tical region or frequency band. Rather, they in-
volved all cortical regions and 2—4 frequency
bands.
2. Two patients with neurological items had com-
pletely normal scores, the third (patient no. 14)
had a single abnormal one. This girl had a doc-
umented history of cerebral concussion, many
years before the ﬁrst absence seizure. However,
no residual damage was present by neurologi-
cal investigation and the recent cranial MRI was
normal, too.
3. Patients with true pharmacoresistance but no
neuro-psychiatric items (patients no. 12 and 21)
showed selective involvement of the delta band:
unusually low negative delta scores were found
in all regions. Patient no. 18 with pharmacore-
sistance and psychopathology showed abnormal
positive scores.
4. In the group of the uncomplicated IGE patients,
23/24 had normal QEEG. Out of them, 19 pa-
tients had not abnormal scores at all one, or
two abnormal scores were found in 3 and 1
patients, respectively. Pathological QEEG (as
deﬁned above) was found in one uncomplicated
patient (patient no. 19). The reason for this
pathological QEEG ﬁnding remained hidden.
5. The comparison of the clinically uncomplicated
and complicated groups showed that the former
is associated with normal QEEG while the latter
with abnormal QEEG (Table 2, P < 0.001).
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Table 2 Relationship of clinical and QEEG ﬁndings
(for deﬁnitions, see text).
IGE patients
Complicated Uncomplicated All




All 11 24 35
Chi-square test (P < 0.001).
Discussion
In this prospectively, randomly collected sam-
ple of newly diagnosed, unmedicated IGE pa-
tients, so-called complicating factors (neurologi-
cal, psychiatric symptoms, pathological personality
traits, true pharmacoresistance) were present in
11/35. Roughly the same proportion of patients
with these complicating factors was reported by
other authors.3—5,19 We found that some sorts of
psychopathology (personality disorder, pseudo-
seizures) were not recognised at the ﬁrst clinical
visit. Our impression was that psychological support
contributed to effective treatment of our patients
with psychopathology. Thus, we agree that these
conditions should be recognised and managed as
soon as possible.4,8
The QEEG method we used is simple and can be
reproduced without difﬁculty. Standard data acqui-
sition and sampling allow 80—90% reproducibility of
the univariate QEEG variables.24 This degree of re-
producibility is roughly equal to test—retest vari-
ability of the same spectral parameters.25 It was
disclosed that one can rely on the normative means
of the NAS database independent of race and geo-
graphical differences.26
Our results conﬁrmed the hypotheses that (1)
IGE patients do not have the same degree of
QEEG-deﬁned cortical dysfunction, and (2) higher
degree of QEEG abnormality corresponds to higher
degree of cortical dysfunction. All but one (23/24)
uncomplicated IGE patients with lesser degree of
cortical dysfunction (as presumed by clinical re-
sults) had normal QEEG. In contrast, one group of
the patients with presumed higher degree of corti-
cal dysfunction (all the patients with psychopathol-
ogy and/or pharmacoresistance) had pathological
QEEG. Our results indicate that QEEG may be a use-
ful method in differentiating between IGE patients
with and without psychopathology at the beginning
of the illness. QEEG alterations are not speciﬁc,
however. The pattern of the spectral alterations
(in terms of topography and frequency band) can-
not differentiate between patients with diverse
psychopathology like personality disorder,4 men-
tal subnormality, or a tendency toward developing
pseudoseizures or self-stimulation. Introduction of
multivariate QEEG parameters might contribute
to this issue.24,26 An alternative possibility is that
mild diffuse derangement of cortical functions may
be a non-speciﬁc predisposition to a variety of
psychopathological disturbances.28
The neurophysiological basis of the association
between psychopathology and abnormal QEEG has
not been clariﬁed yet. Increased volume of corti-
cal grey matter,18 seemingly subtle developmen-
tal abnormalities13 can indicate the presence of
widespread anomalous neuronal connections in IGE
patients. Altered networks can be the pathologi-
cal basis of enhanced neuronal synchronisation,27
and in turn, increased spectral power. According
to another hypothesis, aspeciﬁc ‘‘thalamocortical
dysrhythmia’’ governed by T-type Ca2+ channels
may be common to a few neurological conditions
including epilepsy.29 Interestingly, valproate, a
drug that blocks T-type Ca2+ channels30 partly re-
versed pathological delta—theta power excess in
IGE patients.31
In contrast to psychopathology, neurological
items were not accompanied by abnormal QEEG.
Pathological items in medical history and mild
neurological signs do not necessarily indicate sig-
niﬁcant cortical dysfunction, however.
Both patients with pure pharmacoresistance
showed the same unique ﬁnding, signiﬁcant delta
power decrease all over the scalp. This pattern of
abnormal QEEG was not found in other IGE patients.
The results of two patients cannot be managed as
a proven scientiﬁc ﬁnding, however. In order to
elaborate this issue, a long-term prospective study
is underway.
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